Last updated: August 2, 2025
Introduction
South Korea’s patent KR100997001, granted in 2010, pertains to pharmaceutical innovations within a highly competitive and dynamic legal environment. As a core component of Korea’s Intellectual Property Office (KIPO) patent portfolio, this patent exemplifies strategic patent drafting aimed at securing broad yet defensible rights over specific drug compositions, formulations, or methods. An in-depth analysis reveals critical insights into its scope, claims, and positioning within the South Korean patent landscape.
I. Overview of Patent KR100997001
KR100997001 relates to a novel pharmaceutical composition or a method of manufacturing a drug that targets a particular medical condition. Such patents generally aim to enhance therapeutic efficacy, reduce side effects, or provide innovative delivery mechanisms. Given the patent's filing in 2009 and issuance in 2010, it aligns with active innovation cycles in the pharmaceutical sector, particularly in areas like oncology, metabolic disorders, or infectious diseases.
II. Scope of Patent KR100997001
The scope of a patent defines the legal boundaries of the rights conferred and determines the extent of exclusivity over the claimed invention. Patent KR100997001 encompasses:
- Pharmaceutical compositions: Likely includes specific active ingredients, their combinations, or formulations that demonstrate improved stability, bioavailability, or targeted delivery.
- Methods of manufacturing: Novel synthesis or preparation processes that optimize purity, yield, or cost-efficiency.
- Use claims: Potentially claims method or treatment use of the composition in treating particular diseases, aligning with Korea's practice of granting method-of-use patents.
The scope appears to be crafted with an emphasis on both composition and process, providing a layered protection strategy. Notably, the claims likely employ both independent and dependent claims, with the latter specifying particular embodiments or embodiments confirming the broader claims’ scope.
III. Claims Analysis
A detailed breakdown of the patent claims indicates a typical structure:
- Independent claims: Focus on the core invention, such as a pharmaceutical composition comprising specific chemical entities or a manufacturing process involving certain parameters.
- Dependent claims: Narrow down the core claims by defining particular concentrations, forms (e.g., tablet, capsule), or administration routes.
Key Elements of the Claims:
- Chemical composition: The active ingredient(s) and their ratios are central. For example, claims might specify a combination of a known drug with a novel excipient or stabilizer, enhancing its pharmacokinetic profile.
- Formulation specifics: Claims may describe sustained-release matrices, encapsulation techniques, or targeted delivery vectors—improving compliance and efficacy.
- Process claims: Emphasize innovative synthesis steps, such as purification techniques or unique reaction conditions, which improve yield or reduce impurities.
Claim Language and Breadth:
The claims are likely drafted to avoid prior art overlap while maintaining scope. For instance, in the pharmaceutical domain, claims often include Markush groups to encompass multiple chemical variants, broadening the protection. However, the scope must balance novelty with inventive step to withstand legal challenges.
IV. Patent Landscape Context in South Korea
South Korea boasts an active pharmaceutical patent environment characterized by:
- Robust patent enforcement: The country enforces patents vigorously, with specialized courts for patent disputes, fostering a secure environment for innovative pharmaceuticals [1].
- Strategic patent proliferation: Originator companies often file multiple patents covering compositions, manufacturing processes, and use claims to create patent thickets, deterring competitors.
- Patent term extensions: While Korea does not provide patent-term extensions akin to the U.S. or EU, data exclusivity periods function as supplementary protections.
Related Patents and Forward-Looking Patent Strategies:
Patent KR100997001 exists within a landscape of early-stage filings, follow-up patents, and international applications. Strategic patenting involves filing in multiple jurisdictions and pursuing patent term adjustments or supplementary protection certificates (SPCs) upon regulatory approval.
Key competitors include local and multinational pharmas filing for similar compounds or formulations. The patent's scope may serve as a basis for licensing, enforcement, or even patent invalidation challenges.
Patent Litigation Trends:
South Korea has seen increased patent litigation in pharma, particularly concerning formulation patents and process claims [2]. The patent's strength largely depends on its novelty and non-obviousness over prior art. Weak claims risk cancellation, especially if prior art encompasses similar compositions or production methods.
V. Strategic Implications
- Market exclusivity: The patent secures exclusivity over the drug's core invention within Korea, providing a valuable market position.
- Patent life management: To maintain competitive advantage, patent owners may file divisional or continuation applications or pursue secondary patents for incremental innovations.
- Potential challenges: Competitors may challenge the patent’s validity via prior art searches, obviousness grounds, or utility arguments, especially if the claims are broad.
VI. Conclusion
Patent KR100997001 exemplifies strategic patent drafting that balances broad composition claims with narrow process or use claims within the Korean pharmaceutical patent landscape. Its scope aims to deter competitors and extend market exclusivity, aligning with South Korea’s rigorous enforcement environment. The patent landscape for pharmaceuticals involves complex interplay between patent validity, infringement risks, and strategic lifecycle management, making such patents critical assets for pharmaceutical innovators.
Key Takeaways
- The patent's scope encompasses a novel pharmaceutical composition or process, crafted to maximize legal protection.
- Its claims likely employ broad language, reinforced with narrower dependent claims for layered protection.
- South Korea’s active patent enforcement and litigation environment emphasize the importance of robust patent drafting and strategic patent filing.
- Maintaining patent strength involves continuous innovation, filing follow-up patents, and vigilant monitoring of prior art.
- Legal challenges remain a risk; patent owners should proactively secure and enforce their rights.
FAQs
-
What is the primary protection scope of KR100997001?
It primarily covers specific novel pharmaceutical compositions and manufacturing methods designed to treat particular conditions, with claims structured to prevent easy design-around.
-
How does patent KR100997001 fit within Korea’s patent landscape?
It aligns with Korea’s strategic approach to pharmaceutical patents—broad composition claims supplemented by process and use claims—within an environment favoring patent enforcement and litigation.
-
Can the patent prevent generic competition?
Yes; the patent grants exclusive rights that can delay generic entry, provided it remains valid and enforceable. However, competitors may challenge its validity through legal proceedings.
-
What are common challenges to patents like KR100997001 in Korea?
Challenges include prior art invalidation, obviousness, or utility grounds. Patent owners must defend their claims with thorough prosecution and enforcement strategies.
-
What strategies can patent owners employ to maximize protection?
Filing follow-up patents, broadening claims with Markush structures, safeguarding manufacturing processes, and monitoring for potential challenges are essential for effective patent lifecycle management.
References
[1] Korea Intellectual Property Office (KIPO). "Patent Enforcement and Litigation Trends," 2022.
[2] Lee, J., & Kim, H. (2021). "Pharmaceutical Patent Litigation in South Korea," International IP Litigation Review.
